Home > Company News > Sygnature Chemical Services and Cyprotex Establish Strategic Alliance
Sygnature Chemical Services and Cyprotex Establish Strategic Alliance
December 9th 2009
Nottingham and Macclesfield, UK – 9th December 2009 – Sygnature Chemical Services Ltd., a leading provider of medicinal and computational chemistry services to the global pharmaceutical industry, and Cyprotex Discovery Ltd., a world-renowned pre-clinical discovery and development CRO with a core focus on ADME/PK, today announced they have entered into a strategic alliance. Under the terms of the agreement, Sygnature and Cyprotex will collaborate to provide a fully-integrated discovery chemistry/DMPK service to accelerate their clients’ drug discovery projects into development.
Dr Anthony Baxter, Chief Executive Offer at Cyprotex said, "We are pleased to have formed a strategic alliance with Sygnature. Over the past 5 years, they have established a reputation for high-quality medicinal chemistry, and for the intellectual input they contribute into projects. Cyprotex is known as a centre of excellence for ADME/PK services and we are the first choice CRO for many biotech and big pharma companies. Sygnature is a centre of excellence for medicinal chemistry and has an impressive track record. By working closely together with our customers, who will be experts in their particular therapeutic project field, we are confident that we can accelerate projects forward more effectively than CROs that offer a one-stop-shop approach. My colleagues and I are looking forward to working with the Sygnature team to offer an outstanding fully-integrated discovery chemistry/ADME/DMPK service.”
Commenting on the partnership, Dr Simon Hirst, Sygnature’s CEO said, “Cyprotex has an enviable reputation as a CRO which provides premium ADME/PK services, so I am delighted that we will be working together to offer clients an exceptional, integrated discovery chemistry/DMPK service. At Sygnature we strongly believe that modern drug discovery requires the marriage of medicinal chemistry, ADME and biology. Our medicinal chemists are experienced in using ADME data to drive programmes forward and into proof-of-concept in vivo studies. For the past 18 months, Sygnature and Cyprotex have been collaborating on a drug discovery programme for a customer. Hence, scientists from both organisations already know each other well and have established project management systems in place. I am confident that other customers will see the advantages of a medicinal chemistry-driven service which takes advantage of a faster turnaround of ADME/DMPK data to help determine the discovery chemistry strategy of the project.”
About Sygnature Chemical Services Ltd. Sygnature CSL, founded in 2004, is a leading Nottingham, UK-based provider of premium medicinal chemistry, synthetic chemistry, array/focused library and computational chemistry services. The Company delivers high value and quality to its clients by applying in-house scientific expertise and ‘state-of-the-art’ technologies to the discovery of novel drug candidates. Sygnature’s team of 34 industry-experienced chemists (75% with PhDs) undertakes key elements of the drug discovery process, such as hit identification, hit-to-lead and lead optimisation, to afford novel compounds in a time-efficient and cost-effective manner. We work closely with our clients’ scientists to accelerate their drug candidates into development and thereby increase the value of their R&D discovery programmes. Over the past five years, Sygnature has established an enviable reputation and excellent track record of success with an international client base.
About Cyprotex PLC Cyprotex is based in Macclesfield, near Manchester in the UK, and is listed on the AIM market of the London Stock Exchange (CRX). The company was established in 1999 and works with more than 200 partners ranging from small biotechs to large pharma companies. Cyprotex provides support for a wide range of experimental and computational ADME and PK services, extending from early drug discovery through to IND submission. The company’s core capabilities include Cloe® Screen (high quality in vitro ADME screening service), Cloe® Select (bespoke experimental service focused on later stage ADME and DMPK) and Cloe® Predict (predictive modelling using PBPK and QSAR techniques, including Cloe® PK for in vivo PK prediction).